Showing results (501-510 of 517) with videos related to
Sort By:
Pageof 52
Diseases (Basel, Switzerland)|November 25, 2018
DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based VaccinesGustavo Cabral-Miranda, Ahmed M Salman, Mona O Mohsen, et al.Allergy|April 11, 2022
Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concernDominik A Rothen, Pascal S Krenger, Aleksandra Nonic, et al.Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.Immunity|March 29, 2022
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sitesAndrew J MacLean, Niamh Richmond, Lada Koneva, et al.The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.Thrombosis and Haemostasis|May 3, 2013
Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart DiseaseR De Caterina, S Husted, L Wallentin, et al.Allergy|March 8, 2023
The next generation virus-like particle platform for the treatment of peanut allergyJan M Sobczak, Pascal S Krenger, Federico Storni, et al.Annals of Medicine|February 8, 2022
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccinesQueenie Fernandes, Varghese Philipose Inchakalody, Maysaloun Merhi, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.Allergy|November 28, 2019
State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)Erika Jensen-Jarolim, Martin F Bachmann, Sergio Bonini, et al.Pageof 52